Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label gantenerumab in Alzheimer's disease (Japan rollover from WN29922/WN39658)
jRCT2031200328Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label trial of gantenerumab in Alzheimer's disease (AD) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Score and 3 more. Started Feb 2021; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031200328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200328.